Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 2/20 | 0.43 |
| ▸ | PLAU | P00749 | 2/20 | 0.43 |
| ▸ | CDK4 | P11802 | 8/20 | 0.40 |
| ▸ | CCND1 | P24385 | 8/20 | 0.40 |
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | HTR2C | P28335 | 5/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16216132 | 0.85 | HTR7 (0.44) | PLGPLAUCDK4CCND1HTR2A | |
| SCHEMBL24669590 | 0.85 | PLG (0.45) | PLGPLAUCDK4CCND1HTR2A | |
| SCHEMBL31735936 | 0.81 | GLO1 (0.46) | PLGPLAUHTR2AHTR2C | |
| SCHEMBL30672832 | 0.81 | PRKCI (0.55) | PLGPLAUCDK4CCND1HTR2A | |
| SCHEMBL16370787 | 0.81 | PRKCI (0.55) | PLGPLAUCDK4CCND1HTR2A | |
| SCHEMBL10109815 | 0.81 | RORC (0.43) | PLGPLAUHTR2AHTR2C | |
| SCHEMBL10305068 | 0.78 | PLAU (0.47) | PLGPLAU | |
| SCHEMBL13158646 | 0.78 | PLAU (0.47) | PLGPLAU | |
| SCHEMBL19553339 | 0.77 | HTR2C (0.53) | PLGPLAUHTR2AHTR2C | |
| SCHEMBL110146 | 0.77 | PRKCI (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200397927-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| EP-3567029-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | Lantheus Medical Imaging, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20170266326-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9550000-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20140328756-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266326-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | PLG 1067/4885PLAU 1713/4885CDK4 3459/4885 |
| US-20140328756-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | PLG 1067/4885PLAU 1713/4885CDK4 3459/4885 |
| US-20200397927-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | PLG 1067/4885PLAU 1713/4885CDK4 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.